Table 1 Patient demographics and baseline disease characteristics
Lumiracoxib 100 mg od (n = 811) | Lumiracoxib 100 mg od with initial dose (n = 805) | Celecoxib 200 mg od (n = 813) | Placebo (n = 806) | |
|---|---|---|---|---|
Age in years, mean ± SD | 61.3 ± 10.6 | 61.9 ± 10.3 | 61.6 ± 10.6 | 61.3 ± 10.4 |
Females, n (%) | 526 (64.9) | 539 (67.0) | 535 (65.8) | 539 (66.9) |
Body mass index in kg/m2, mean ± SD | 31.2 ± 6.3 | 31.2 ± 6.1 | 31.1 ± 6.5 | 31.1 ± 6.2 |
Race, n (%) | ||||
Caucasian | 773 (95.3) | 755 (93.8) | 756 (93.0) | 765 (94.9) |
Black/African-American | 19 (2.3) | 20 (2.5) | 30 (3.7) | 19 (2.4) |
Disease duration in years, mean ± SD | 5.6 ± 6.8 | 5.6 ± 7.3 | 5.5 ± 6.9 | 5.4 ± 6.6 |
Baseline OA pain intensity (VAS [mm]) | 65.2 (13.8) | 64.9 (13.7) | 65.6 (13.8) | 64.9 (13.2) |
Baseline patient's global assessment of disease activity (VAS [mm]) | 63.1 (17.2) | 62.7 (17.1) | 62.3 (17.7) | 62.7 (16.6) |
Baseline WOMAC™ LK 3.1 Function score (VAS) | 36.2 (10.8) | 36.4 (11.3) | 36.6 (10.9) | 36.5 (10.7) |